Lantheus Holdings, Inc. · NASDAQ:LNTH
Lantheus — Q4 2024 Earnings Presentation
30 slides from Lantheus's earnings presentation, Feb 26, 2025
Slide 1: Fourth Quarter & FY2024 Results
Lantheus Fourth Quarter & FY2024 Results February 26, 2025 © 2025 Lantheus. All rights reserved.
Slide 2: Agenda
Agenda Highlights & Operational Financial Closing Q&A Business Update Update Update Remarks Session Brian Markison Paul Blanchfield Bob Marshall Amanda Morgan Mark Kinarney CEO President CFO and Treasurer Chief Commercial Vice President, Officer Investor Relations © 2025 Lantheus. All rights reserve
Slide 3: Safe Harbor Statements
Safe Harbor Statements Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe har
Slide 4: Agenda
Agenda Highlights & Operational Financial Closing Q&A Business Update Update Update Remarks Session Brian Markison Paul Blanchfield Bob Marshall Amanda Morgan Mark Kinarney CEO President CFO and Treasurer Chief Commercial Vice President, Officer Investor Relations © 2025 Lantheus. All rights reserve
Slide 5: Strengthened Focus & Foundation Drive Momentum into 2025
Lantheus: Strengthened Focus & Foundation Drive Momentum into 2025 2024 Key Drivers of Success Key Recent Strategic Announcements* • Adds Neuraceq, an approved PET radiodiagnostic, and commercial franchise • Enhances R&D & clinical development capabilities 2024 Pipeline Additions NAV-4694 LNTH-2401
Slide 6: Agenda
Agenda Highlights & Operational Financial Closing Q&A Business Update Update Update Remarks Session Brian Markison Paul Blanchfield Bob Marshall Amanda Morgan Mark Kinarney CEO President CFO and Treasurer Chief Commercial Vice President, Officer Investor Relations © 2025 Lantheus. All rights reserve
Slide 7: PYLARIFY Blockbuster Status
Utilized PSMA PET Imaging Agent1 4Q 2024 FIRST $266.0M +15.7% Growth RADIODIAGNOSTIC 4Q 2024 Net Sales 4Q 2024 Year-over-Year TO ACHIEVE FY 2024 BLOCKBUSTER $1.058B +24.3% Growth STATUS FY 2024 Net Sales FY 2024 Year-over-Year >225,000 PYLARIFY scans performed in 20241 1. Internal analyses and data
Slide 8: PSMA PET Market Could Reach $3.5B+ by the End of the Decade
PSMA PET Market Could Reach $3.5B+ by the End of the Decade U.S. PSMA PET Imaging Annual Market & Scan Potential ~750K ANNUAL SCANS ~525K ~175K Vast majority of our hospital and free-standing imaging ANNUAL SCANS business under strategic partnership agreements INITIAL STAGING FOR SUSPECTED ~145K MET
Slide 9: DEFINITY: #1 Utilized Ultrasound Enhancing Agent
#1 Utilized Ultrasound Enhancing Agent1 4Q 2024 $86.2M +17.9% Growth 4Q 2024 Net Sales 4Q 2024 Year-over-Year FY 2024 $317.8M +13.6% Growth FY 2024 Net Sales FY 2024 Year-over-Year Used in echocardiography exams for >3.5M patients in 20242 1. DRG Real World Data (RWD) report; 2. Internal analyses an
Slide 10: The Expanding Role of Radiodiagnostics in Alzheimer's Disease
The Expanding Role of Radiodiagnostics in Alzheimer’s Disease Alzheimer’s Disease PET Imaging Annual Market & Scan Potential ~$1.5B1 SCREENING ~80K 90% STAGING ~300K recently updated their of ~300 dementia experts guidelines2,3 to expand the surveyed project Tau PET to add value to clinical appropri
Slide 11: Innovation that Makes an Impact
Innovation that Makes an Impact Expanding Pipeline of Radiopharmaceuticals Candidate Target Isotope Indication/Disease Area Pre-Clinical Phase I Phase II Phase III Reg. Filing PNT20021 PSMA 177Lu Metastatic Prostate Cancer Prostate LNTH-24012 GRPR 68Ga Metastatic Prostate Cancer Cancer LNTH-24023 GR
Slide 12: Agenda
Agenda Highlights & Operational Financial Closing Q&A Business Update Update Update Remarks Session Brian Markison Paul Blanchfield Bob Marshall Amanda Morgan Mark Kinarney CEO President CFO and Treasurer Chief Commercial Vice President, Officer Investor Relations © 2025 Lantheus. All rights reserve
Slide 13: Continued Strong Financial Performance in 4Q & FY 2024
Continued Strong Financial Performance in 4Q & FY 2024 Total Revenue USD Millions Other Precision Diagnostics +$237.5 +18.3% Strategic Partnerships & Other INCREASE TechneLite $25.1 (+16.7%) DEFINITY $1,533.9 $86.2 (+17.9%) $1,296.4 PYLARIFY +$37.1 $266.0 (+15.7%) INCREASE +10.5% $354.0 $391.1 4Q 20
Slide 14: Lantheus 4Q & FY 2024 Financial Highlights
Lantheus 4Q & FY 2024 Financial Highlights1 Adjusted EP +$0.53 +8.6% USD INCREASE 6.76 6.23 -$0.16 DECREASE -9.0% 1.75 1.59 4Q 2023 4Q 2024 FY 2023 FY 2024 Solid Year-over-Year Growth Amidst Investment for Future Growth 1. See slide 26 for a reconciliation of GAAP to non-GAAP financials; certain amo
Slide 15: Growing Capital Resources Provide Financial Flexibility
Growing Capital Resources Provide Financial Flexibility1 Cash Flow Summary Free Cash Flow2 Resources USD Millions (4Q 2024) Three Months Ending December 31 +$41.1 2023 2024 INCREASE Cash provided $112.3 $157.7 $912.8M by operations CASH ON HAND3 Cash used in $141.4 ($12.1) ($6.6) investing $100.2 Ca
Slide 16: Updated FY 2025 Financial Guidance
Updated FY 2025 Financial Guidance1 Guidance Issued February 26, 2025 The Company guidance for the full year 2025 is as follows: Revenue $1.545B – $1.610B FY 2025 Adjusted Fully Diluted EPS2 $7.00 – $7.20 Free Cash Flow to continue to expand throughout 2025 with an anticipated amount of $550M - $600
Slide 17: Agenda
Agenda Highlights & Operational Financial Closing Q&A Business Update Update Update Remarks Session Brian Markison Paul Blanchfield Bob Marshall Amanda Morgan Mark Kinarney CEO President CFO and Treasurer Chief Commercial Vice President, Officer Investor Relations © 2025 Lantheus. All rights reserve
Slide 18: Lantheus, the Leading Radiopharmaceutical-Focused Company
Lantheus, the Leading Radiopharmaceutical-Focused Company Maximize the value of our existing portfolio and expand our innovative pipeline of radiopharmaceuticals through STRATEGY: focused business development and M&A, all while sustaining an attractive financial profile PYLARIFY Focused Clear market
Slide 19: Agenda
Agenda Highlights & Operational Financial Closing Q&A Business Update Update Update Remarks Session Brian Markison Paul Blanchfield Bob Marshall Amanda Morgan Mark Kinarney CEO President CFO and Treasurer Chief Commercial Vice President, Officer Investor Relations © 2025 Lantheus. All rights reserve
Slide 20: Appendix
Appendix © 2025 Lantheus. All rights reserved. 20
Slide 21: Recent Acquisition Agreements Will Enhance Capabilities Across Radiopharmaceutical Value Chain
Recent Acquisition Agreements Will Enhance Capabilities Across Radiopharmaceutical Value Chain Accelerates Innovation for Patients in the Growing Enhances Capabilities as a Fully Integrated Alzheimer’s Disease Radiodiagnostic Space Radiopharmaceutical Company TRANSACTION SUMMARY • Upfront payment of
Slide 22: Condensed Consolidated Statement of Operations – 4Q 2024
Condensed Consolidated Statement of Operations – 4Q 2024 © 2025 Lantheus. All rights reserved. 22
Slide 23: As Adjusted Condensed Consolidated Statement of Operations – 4Q 2024
As Adjusted Condensed Consolidated Statement of Operations – 4Q 2024 © 2025 Lantheus. All rights reserved.5 23
Slide 24: Condensed Consolidated Statement of Operations – FY 2024
Condensed Consolidated Statement of Operations – FY 2024 © 2025 Lantheus. All rights reserved. 24
Slide 25: As Adjusted Condensed Consolidated Statement of Operations – FY 2024
As Adjusted Condensed Consolidated Statement of Operations – FY 2024 © 2025 Lantheus. All rights reserved. 25
Slide 26: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP to Non-GAAP Financial Measures (in thousands, except per share data – unaudited) (a) The income tax effect of the adjustments between GAAP net income and adjusted net income (non-GAAP) takes into account the tax treatment and related tax rate that apply to each adjustment in t
Slide 27: Consolidated Statement of Operations
Consolidated Statement of Operations (in thousands, except per share data) © 2025 Lantheus. All rights reserved. 27
Slide 28: Consolidated Segment Revenues Analysis
Consolidated Segment Revenues Analysis (in thousands) © 2025 Lantheus. All rights reserved. 28
Slide 29: Reconciliation of Free Cash Flow
Reconciliation of Free Cash Flow (in thousands) © 2025 Lantheus. All rights reserved. 29
Slide 30: Condensed Consolidated Balance Sheet
Condensed Consolidated Balance Sheet (in thousands) © 2025 Lantheus. All rights reserved. 30